NASDAQ$BBIO
Bridgebio Pharma Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results and business update for Q2 2021, highlighted by FDA approval for TRUSELTIQ™ and Fast Track designations for encaleret and gene therapy for CAH.
BridgeBio Pharma reported its Q2 2021 financial results, with a key highlight being the FDA approval of TRUSELTIQ™ for cholangiocarcinoma. The company ended the quarter with $898.4 million in cash, cash equivalents, and marketable securities. Total revenues for the quarter were $54.0 million, and operating costs and expenses were $148.0 million.
- Received FDA approval for TRUSELTIQ™ (infigratinib) for cholangiocarcinoma (CCA).
- Received FDA Fast Track designation for encaleret for autosomal dominant hypocalcemia (ADH1).
- Received FDA Fast Track designation for gene therapy for congenital adrenal hyperplasia (CAH).
- Ended the quarter with $898.4 million in cash, cash equivalents and marketable securities.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$54M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio anticipates major milestones in the next 12 months across its core value drivers, including topline results for Acoramidis, additional data for Encaleret, initial data for low-dose Infigratinib, and initial data for BBP-631.
Tailwinds
- Topline results from Part A of the ATTRibute-CM trial of acoramidis are expected in late 2021.
- Additional data from the ongoing study of encaleret for ADH1 are expected in the second half of 2021.
- Initial data from the ongoing Phase 2 dose ranging study of infigratinib for achondroplasia are expected in the first half of 2022.
- Initial data from the ongoing Phase 1/2 study of BBP-631 for CAH are anticipated in mid-2022.
- BridgeBio is eligible to receive future milestone payments under its strategic collaboration with the Helsinn Group.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro